NeOnc Technologies Holdings, Inc. has announced promising early clinical results from its investigational treatment, NEO100, in a pediatric patient in Abu Dhabi. This development is significant for the company as it highlights the potential of its innovative therapies in treating serious conditions.
On October 16, 2026, NeOnc revealed that a three-year-old boy, critically ill with an aggressive brain tumor, showed early signs of improvement after receiving NEO100 through the company’s Compassionate Care program. The child's treating physicians reported that he is now breathing independently and beginning to move his legs, a notable change given his previous condition.
NeOnc, a clinical-stage biopharmaceutical company, focuses on developing therapies for central nervous system cancers. The company trades on the Nasdaq under the ticker symbol NTHI and is classified under the SIC code 2834, which pertains to pharmaceutical preparations. Recent filings indicate that NeOnc is an emerging growth company, actively seeking to expand its clinical programs.
The filing dated October 22, 2026, includes multiple updates from the company. Notably, it mentions a Memorandum of Understanding (MoU) signed with the Department of Health - Abu Dhabi to collaborate on developing research and clinical capabilities in oncology and central nervous system therapeutics. This partnership is expected to enhance NeOnc's research capabilities and expand its presence in the UAE.
Further emphasizing its outreach, NeOnc also announced that it would be featured on the national health television series, Health Uncensored with Dr. Drew, discussing non-invasive approaches to delivering investigational therapies to brain tumors. This exposure could help raise awareness and support for its innovative treatment approaches.
Amir H. Heshmatpour, CEO of NeOnc, expressed his gratitude towards the treating physicians and the Department of Health - Abu Dhabi for facilitating the treatment access. He stated, “Hearing that this little boy is breathing on his own and beginning to move his legs is profoundly moving. For his family, every sign of progress matters.”
Dr. Thomas Chen, Chief Medical Officer of NeOnc, noted that while the reported improvements are encouraging, they do not establish the safety or efficacy of NEO100. The company is committed to systematically evaluating NEO100 in its pediatric clinical program.
NEO100 is a highly purified form of perillyl alcohol administered intranasally, designed to provide a non-invasive route to the brain. As an investigational drug, its safety and efficacy have not yet been established in pediatric patients.
This recent update from NeOnc is part of its broader strategy to develop therapies for central nervous system cancers, which are often challenging to treat. The collaboration with the Department of Health - Abu Dhabi and the early clinical results from the Compassionate Care program could significantly impact the company’s future and the pharmaceutical preparations industry.
As NeOnc continues to advance its clinical programs, the industry will be watching closely to see how these developments unfold. The company has indicated that further updates will follow as it progresses with its clinical trials and partnerships.
Details were not available in the SEC filing regarding the next steps for NeOnc following these announcements.